Dr. Ramalingam on Treatment Parameters for Osimertinib in Lung Cancer
Suresh S. Ramalingam, MD, FASCO, discusses the current treatment parameters for osimertinib in EGFR-mutant non–small cell lung cancer and ongoing research with the agent.
Suresh S. Ramalingam, MD, FASCO, deputy director of Winship Cancer Institute of Emory University, discusses the current treatment parameters for osimertinib (Tagrisso) in EGFR-mutant non—small cell lung cancer and ongoing research with the agent.
Patients diagnosed with lung adenocarcinoma or nonsquamous lung cancer receive molecular testing, and treatment should be held until the results are given, explains Ramalingam. For patients with EGFR exon 19 or exon 21 mutations, the frontline therapy is osimertinib outside of a clinical trial.
An ECOG trial examining osimertinib plus bevacizumab (Avastin) versus osimertinib alone will soon launch and give insight on combining another targeted agent with the best-in-class TKI inhibitor, says Ramalingam. Research is also looking into understanding the mechanisms of resistance to osimertinib and developing novel approaches to delay or overcome resistance, concludes Ramalingam.
